Skip to main content
letter
. 2020 May 27;190(1):e16–e20. doi: 10.1111/bjh.16801

Fig 1.

Fig 1

Overall survival according to haematologic malignancy diagnosis previous to SARS‐CoV‐2 infection. (A) Overall survival according to haematologic treatment purpose at the time of illness onset, excluded five cases on life support. (B) Overall survival depending on qSOFA, CURB‐65 and ECOG PS at first hospital admission or at COVID‐19 onset. (C) Overall survival according to the development of moderate or severe ARDS during hospitalisation period.